This federal contract award is for the delivery of KIMMTRAK (tebentafusp-tebn), a 100MCG/0.5ML injectable pharmaceutical product, to the U.S. Department of Veterans Affairs (VA). The contract was awarded to Immunocore Commercial LLC, a foreign-owned, for-profit manufacturer of goods, through a Total Small Business set-aside. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $14,447.83 and an ultimate completion date of June 30, 2025. Immunocore Commercial LLC holds two...
This federal contract award is for the delivery of KIMMTRAK (tebentafusp-tebn), a 100MCG/0.5ML injectable pharmaceutical product, to the U.S. Department of Veterans Affairs (VA). The contract was awarded to Immunocore Commercial LLC, a foreign-owned, for-profit manufacturer of goods, and is a Firm Fixed Price Delivery Order under the company's $225,000 Federal Supply Schedule (FSS) Indefinite Delivery Vehicle (IDV) contract 36F79724D0026. This IDV covers Federal Supply Classification 65 I B,...
This federal contract award was made by the U.S. Department of Veterans Affairs (VA) to Immunocore Commercial LLC, a foreign-owned, for-profit manufacturer of pharmaceutical products. The $14,726.35 firm fixed-price delivery order is for the supply of the drug KIMMTRAK (tebentafusp-tebn), a 100MCG/0.5ML injectable pharmaceutical product, to the VA's Veterans Integrated Service Network (VISN) 9. The contract is not designated as a set-aside and is part of a larger $225,000 Indefinite Delivery...
This is a firm fixed-price delivery order for the pharmaceutical product KIMMTRAK (tebentafusp-tebn) 100MCG/0.5ML, awarded by the Department of Veterans Affairs (VA) to Immunocore Commercial LLC, a foreign-owned, for-profit manufacturer of goods. The $88,802.10 contract has an ultimate completion date of March 31, 2025 and was not set aside for any socioeconomic program. Immunocore Commercial LLC holds two primary Federal Supply Schedule (FSS) Indefinite Delivery Vehicles (IDVs) with the VA,...
This federal contract award is for the delivery of KIMMTRAK (tebentafusp-tebn) 100MCG/0.5ML vials, an injectable pharmaceutical product, to the U.S. Department of Veterans Affairs (VA). The prime contractor, Immunocore Commercial LLC, is a foreign-owned, for-profit manufacturer of goods registered in the System for Award Management (SAM.gov). The contract, a firm fixed-price delivery order with a ceiling value of $86,686.98, was awarded on October 11, 2024, with an ultimate completion date of...
This federal contract award was issued by the U.S. Department of Veterans Affairs (VA) to Immunocore Commercial LLC, a foreign-owned, for-profit manufacturer of pharmaceutical goods. The $28,895.66 firm fixed-price delivery order is for the supply of KIMMTRAK (tebentafusp-tebn) 100MCG/0.5ML injectable pharmaceutical product to the VA's Veterans Integrated Service Network (VISN) 21. Immunocore Commercial LLC is the prime contractor and holds two Federal Supply Schedule (FSS) Indefinite Delivery...
This is a firm fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Immunocore Commercial LLC, a foreign-owned for-profit manufacturer of pharmaceutical goods. The contract, valued at $29,452.70, is for the delivery of KIMMTRAK (tebentafusp-tebn), a specialized 100MCG/0.5ML injectable hematology-related pharmaceutical product. The contract is part of a larger Federal Supply Schedule (FSS) Indefinite Delivery Vehicle (IDV) with a $225,000 ceiling value,...
This federal contract award is for the pharmaceutical product Kymriah (tisagenlecleucel), a chimeric antigen receptor T-cell (CAR-T) therapy, provided by the prime contractor Novartis Pharmaceuticals Corporation. The contract has a ceiling value of $283,555.92 and is a Blanket Purchase Agreement (BPA) call under Novartis' Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract was awarded by the Department of Veterans Affairs (VA) and is intended to support...
This federal contract award to Novartis Pharmaceuticals Corporation, doing business as NPS, is for the delivery of Kymriah, a specialized cell therapy cancer treatment, to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract is issued as a delivery order against Novartis' existing Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs, which has a potential value of $5.4 billion and runs through August 2025. The specific delivery...
This is a delivery order award from the Department of Veterans Affairs (VA) Veterans Health Administration to Novartis Pharmaceuticals Corp. (Novartis), a foreign-owned, for-profit manufacturer of pharmaceuticals and drugs. The contract is for the drug product Kymriah, a chimeric antigen receptor T-cell therapy, to support VA medical programs. The delivery order has a firm fixed price of $283,567.92 and was issued against Novartis' Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals...